Lesson
Recognize the Pattern and Protect the Diagnosis
MS is a clinical and paraclinical diagnosis, not a single MRI finding. Current criteria can use more kinds of evidence, but the phenotype and differential diagnosis still determine whether that evidence belongs to MS.
- 2024 McDonald criteria
- Optic nerve
- MRI biomarkers
- CSF kappa free light chains
- Mimics
Connect the attack, examination, optic nerve, brain, brainstem, cerebellum, and spinal cord.
Use characteristic MRI, CSF, optic nerve, central vein, and rim-lesion evidence within defined criteria.
Investigate NMOSD, MOG-associated disease, vascular, infectious, nutritional, compressive, and inflammatory mimics.
Start with the syndrome
Typical presentations include optic neuritis, brainstem or cerebellar syndromes, partial myelitis, and other focal CNS deficits. Time course, objective findings, and lesion location should form one coherent story.
Use the current evidence set
The 2024 McDonald criteria add the optic nerve as a fifth location and incorporate defined uses of the central vein sign, paramagnetic rim lesions, and CSF kappa free light chains. Selected characteristic cases may no longer require the older automatic wait for dissemination in time.
Protect specificity
Migraine, small-vessel ischemia, NMOSD, MOG-associated disease, infection, nutritional deficiency, compression, sarcoidosis, lupus, and other inflammatory disorders can resemble MS. Red flags and atypical lesion patterns require targeted evaluation.
Separate classification from certainty
A criteria-compatible pattern increases diagnostic confidence only when the clinical syndrome is appropriate and better explanations have been addressed. A nonspecific lesion or isolated biomarker cannot carry the diagnosis alone.
Quick check
Lesson
Connect Tissue Injury to the Treatment Target
Inflammation, demyelination, axonal injury, incomplete recovery, and neurodegeneration interact over time. Relapse count alone cannot describe the disease or the treatment target.
- Demyelination
- Axonal injury
- Relapsing activity
- Progression
- Shared selection
Capture new focal dysfunction, recovery, and enhancing or new MRI lesions.
Incomplete recovery and tissue loss can convert attacks into lasting disability.
Measure walking, hand function, cognition, vision, and daily performance over time.
Localize the injury
Myelin loss disrupts conduction, while axonal injury can create irreversible disability. Lesion location explains why the same disease can affect vision, strength, sensation, coordination, cognition, bladder function, or gait.
Distinguish activity from progression
New attacks and enhancing lesions reflect inflammatory activity. Disability can also accumulate gradually without a recognized relapse, so quiet relapse history does not prove complete disease control.
Choose an efficacy strategy
Initial therapy may follow escalation or early high-efficacy reasoning. Disease activity, spinal or infratentorial burden, incomplete recovery, age, comorbidity, pregnancy goals, route, monitoring, access, and preference shape that decision.
Define success before treatment
Document the expected clinical and MRI response, safety schedule, adherence plan, and threshold for switching. A treatment cannot be judged fairly if exposure, onset, and outcome measures remain vague.
Quick check
Lesson
Treat the Attack Without Losing the Long View
A true relapse must be separated from infection, heat, metabolic stress, and recurrence of an old deficit. Acute therapy can speed recovery, but it is not the long-term disease-modifying plan.
- True relapse
- Pseudo-relapse
- High-dose glucocorticoid
- Plasma exchange
- Follow-up
Check infection, fever, heat, metabolic stress, timing, localization, and objective change.
Use acute therapy for functionally important inflammation, not as chronic disease modification.
Move urgently when a severe demyelinating deficit remains steroid refractory.
Confirm new inflammatory dysfunction
Document onset, duration, objective findings, anatomic localization, and impact on daily function. Fever, urinary infection, heat, sleep loss, and metabolic disturbance can temporarily uncover an old deficit.
Treat when function warrants it
High-dose oral or intravenous glucocorticoid regimens can shorten recovery from a disabling relapse. Mild sensory symptoms may not justify the same toxicity, and chronic low-dose prednisone is not DMT.
Escalate severe refractory disease
Plasma exchange can be considered urgently for a severe demyelinating attack that responds inadequately to high-dose glucocorticoids. The decision is time sensitive and specialist directed.
Close the loop
Reassess recovery, rehabilitation, MRI context, adherence, and whether the event represents breakthrough activity. A relapse should update the longitudinal treatment decision, not disappear after the steroid course.
Quick check
Lesson
Use Injectable Platform Therapy Precisely
Glatiramer acetate and interferon beta remain relevant options for selected patients, but their schedules, administration, adverse effects, laboratory plans, and counseling are product specific.
- Glatiramer acetate
- Interferon beta
- Injection rotation
- Flu-like symptoms
- Laboratory monitoring
Rotate sites and distinguish expected immediate reactions from persistent emergencies.
Match route and schedule with flu-like, liver, blood, thyroid, mood, and skin surveillance.
Confirm exposure and continue relapse, MRI, and disability assessment.
Counsel glatiramer completely
Rotate injection sites and address lipoatrophy and skin injury. A transient immediate post-injection reaction can include flushing, chest symptoms, palpitations, anxiety, or dyspnea, but severe, persistent, or atypical symptoms require urgent assessment.
Differentiate interferon products
Interferon beta products use different routes, strengths, and schedules. Flu-like symptoms and injection reactions are common, while liver injury, cytopenias, thyroid abnormalities, mood concerns, and rare serious events require product-specific monitoring.
Design adherence around reality
Needle preference, dexterity, refrigeration, travel, training, schedule burden, and adverse-effect timing influence whether an injectable plan is sustainable.
Do not mistake tolerability for efficacy
A well-tolerated platform therapy still requires relapse, MRI, and disability surveillance. Continued inflammatory activity should trigger a treatment review rather than automatic continuation.
Quick check
Lesson
Build Safety Around Fumarates and Teriflunomide
Oral administration removes injections, not risk. Fumarates and teriflunomide require deliberate blood, liver, infection, reproductive, interaction, and symptom surveillance.
- Dimethyl fumarate
- Diroximel fumarate
- Teriflunomide
- Lymphopenia
- Accelerated elimination
Connect persistent lymphopenia with infection and PML vigilance while managing flushing and GI effects.
Monitor liver, blood, pressure, nerves, infection, interactions, and reproduction.
Apply cholestyramine or activated charcoal and verify low concentrations when rapid removal is required.
Use fumarates with immune surveillance
Dimethyl fumarate and diroximel fumarate can cause flushing and gastrointestinal effects. Track lymphocytes and liver tests, and investigate prolonged lymphopenia, serious infection, or progressive neurologic change for PML and other causes.
Understand teriflunomide persistence
Teriflunomide inhibits pyrimidine synthesis and can affect liver, blood counts, blood pressure, nerves, infection risk, and reproduction. Clinically relevant exposure can persist long after the last tablet.
Know the elimination pathway
Cholestyramine or activated charcoal can accelerate teriflunomide elimination when pregnancy, serious toxicity, or another urgent reason requires it. Laboratory confirmation is part of the process.
Audit the whole regimen
Oral DMTs can interact with transporters, enzymes, vaccines, immunosuppressants, and hepatotoxic medicines. A medication and supplement review is part of each transition.
Quick check
Lesson
Differentiate the S1P Modulators
Fingolimod, siponimod, ozanimod, and ponesimod share lymphocyte sequestration but differ in receptors, labeled populations, titration, genotype, cardiac observation, and safety details.
- Fingolimod
- Siponimod
- Ozanimod
- Ponesimod
- Rebound
Review conduction, medicines, VZV, eyes, liver, blood, lungs, infection, vaccines, and pregnancy.
Apply the correct genotype, titration, and first-dose observation requirements.
Plan interruptions, restart requirements, access, and the next effective therapy before a prolonged gap.
Screen before the first dose
Review ECG and conduction context, rate-slowing medicines, VZV immunity, blood counts, liver function, eye disease, pulmonary history, infection, vaccines, and pregnancy plans. Product differences determine what happens next.
Respect product boundaries
Siponimod uses CYP2C9 genotype information. Titration and first-dose observation differ across products and patients. Macular edema, liver injury, hypertension, respiratory effects, infection, and skin malignancy remain important class concerns.
Plan every interruption
Some interruptions require repeat titration or observation. Longer treatment gaps can expose the patient to disease reactivation, so access failures and infection holds require an explicit restart or switch plan.
Prevent rebound
Severe disease worsening can follow discontinuation, especially when the next effective therapy is delayed. Reproductive transitions and insurance disruptions should be planned before the final dose whenever possible.
Quick check
Lesson
Use High-Efficacy Biologics Without Blurring Their Boundaries
Anti-CD20 therapies and natalizumab can provide strong disease control, but indication, route, schedule, infection risk, vaccine timing, immunoglobulins, liver status, and PML surveillance determine safe use.
- Ocrelizumab
- Ofatumumab
- Ublituximab
- Natalizumab
- PML
Separate ocrelizumab IV and SC, ofatumumab, and ublituximab schedules and indications.
Screen hepatitis B, immunoglobulins, liver, infection, and vaccines before depletion.
Use JCV context, duration, prior exposure, MRI, TOUCH REMS, and urgent symptom evaluation.
Differentiate anti-CD20 products
Ocrelizumab, ofatumumab, and ublituximab deplete CD20-positive B cells but use different schedules and settings. Screen hepatitis B, quantitative immunoglobulins, liver tests, infection, and vaccine status before treatment.
Name the ocrelizumab route
Ocrevus is intravenous, while Ocrevus Zunovo is subcutaneous. The administration process is not interchangeable, so an order and handoff must identify the formulation explicitly.
Build the natalizumab risk system
PML risk is shaped by anti-JCV antibody status, exposure duration, and prior immunosuppressant use. TOUCH REMS, MRI context, interval reassessment, and immediate evaluation of suspicious neurologic change are essential.
Time vaccines and infection decisions
Update indicated vaccines before immune depletion when feasible. Active serious infection, declining immunoglobulins, liver injury, or repeated infections can change dosing and continuation decisions.
Quick check
Lesson
Treat the Course, Then Monitor the Biology
Cladribine and alemtuzumab use time-limited treatment courses to create longer immune effects. Their safety obligations continue after dosing ends.
- Cladribine
- Alemtuzumab
- Immune reconstitution
- REMS
- Delayed toxicity
Screen infection, malignancy, blood, liver, vaccines, interactions, and reproduction.
Pair infusion and prophylaxis with thyroid, renal, blood, skin, infection, and malignancy surveillance.
Preserve laboratory deadlines, symptom triggers, and ownership long after the last dose.
Plan cladribine before dosing
Review infection, vaccination, malignancy screening, blood counts, liver function, pregnancy, contraception, interactions, and cumulative course limits. Its annual courses are not routine daily maintenance.
Use alemtuzumab within its safety system
Infusion reactions, infections, thyroid disease, immune thrombocytopenia, nephropathy, malignancy, and other autoimmune events require REMS-based prophylaxis and prolonged laboratory and clinical monitoring.
Expect delayed consequences
Immune effects outlast the administration window. A normal final infusion day does not end infection, autoimmune, reproductive, or malignancy surveillance.
Preserve continuity
The record should contain every course date, laboratory deadline, vaccine, prophylaxis interval, symptom trigger, contraception window, and responsible clinician.
Quick check
Lesson
Treat Function, Not Just the MRI
DMT reduces future inflammatory activity but does not directly solve every chronic symptom. Rehabilitation and targeted symptom care determine how disease control translates into daily life.
- Dalfampridine
- Spasticity
- Bladder and bowel
- Fatigue and cognition
- Polypharmacy
Combine gait, balance, strength, stretching, energy conservation, equipment, and home safety.
Distinguish spasticity, pain, bladder, bowel, fatigue, sleep, mood, cognition, and sexual health.
Prevent sedation, falls, retention, constipation, and cognitive effects from cumulative symptom therapy.
Use dalfampridine inside its renal boundary
Dalfampridine may improve walking in selected adults. It is contraindicated with seizure history or creatinine clearance of 50 mL/min or less, and extended-release tablets must not be crushed, split, or doubled.
Treat spasticity as a functional problem
Stretching, physical therapy, mobility equipment, trigger control, and selected medicines can reduce painful or disabling tone. Excessive relaxation and sedation can worsen transfers, gait, and falls.
Map bladder, bowel, pain, and fatigue
Retention, urgency, infection, constipation, neuropathic pain, sleep, mood, anemia, thyroid disease, and medication effects require distinct evaluation rather than one nonspecific fatigue label.
Reduce treatment-created disability
Baclofen, gabapentinoids, anticholinergics, cannabinoids, hypnotics, and other symptom medicines can combine into sedation, falls, cognitive burden, constipation, or retention. Review the whole symptom regimen.
Quick check
Lesson
Make the MS Timeline Authoritative
Longitudinal care turns attacks, MRI, disability, exposure, infection, vaccines, laboratory trends, pregnancy goals, access, and treatment transitions into one visible decision record.
- Breakthrough disease
- Switching
- Washout
- Vaccination
- Handoff
Record relapses, MRI, disability, tolerability, exposure, and safety monitoring.
Balance washout, immune recovery, rebound, infection, vaccines, pregnancy, and overlap.
Resolve coverage, travel, storage, training, language, and laboratory barriers before they become a gap.
Measure breakthrough disease
New relapse, enhancing or new MRI lesions, disability progression, intolerance, unsafe monitoring, or inadequate exposure can justify a change. Confirm what the current treatment had a fair chance to accomplish.
Design the transition
Stopping and starting dates, washout, immune recovery, infection, rebound risk, pregnancy, vaccines, and overlapping immunosuppression determine switch safety. The goal is neither an unsafe overlap nor an avoidable untreated gap.
Document the safety calendar
Capture last and next doses, MRI schedule, blood and liver tests, immunoglobulins, JCV status, eye monitoring, vaccines, reproductive plans, infection holds, and restart ownership.
Treat access as clinical
Insurance delay, infusion distance, injection training, storage, language, cost, and monitoring availability change effective exposure. A theoretically ideal medicine that cannot reach the patient is not a complete plan.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Montalban X, et al. 2024 revisions of the McDonald criteria for multiple sclerosis. Lancet Neurology. 2025.
- American Academy of Neurology. Disease-modifying Therapies for Adults with Multiple Sclerosis.
- Department of Veterans Affairs. Disease Modifying Therapies in Multiple Sclerosis. June 2024.
- Department of Veterans Affairs. Relapse Management for Multiple Sclerosis.
- DailyMed. Briumvi Ublituximab Prescribing Information.
- DailyMed. Kesimpta Ofatumumab Prescribing Information.
- DailyMed. Ocrevus Zunovo Prescribing Information.
- DailyMed. Tysabri Natalizumab Prescribing Information.
- DailyMed. Ampyra Dalfampridine Prescribing Information.
- National Multiple Sclerosis Society. Disease-modifying therapies.